Derma Sciences, Inc. Engages Plexus Ventures to Explore Strategic Options for DSC127 Outside the U.S.

Published: May 14, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that it has engaged Plexus Ventures, a leading strategic advisor to the pharmaceutical, biotechnology and drug delivery industries worldwide, to explore options for DSC127 outside the U.S. The process is expected to take nine to 15 months and to culminate with one or more agreements covering specific geographies or countries in Europe, Asia and emerging markets. DSC127 is Derma Science’s topical drug candidate currently in two Phase 3 trials in the U.S. for the treatment of diabetic foot ulcers.

Help employers find you! Check out all the jobs and post your resume.

Back to news